AVITA Medical Appoints Cary Vance as Permanent CEO Following Successful Interim Leadership
Key Insights
AVITA Medical's Board of Directors has appointed Cary Vance as President and Chief Executive Officer effective immediately, following his successful six-month tenure as Interim CEO since October 2025.
The appointment follows a thorough search process conducted with an international executive search firm, with the Board unanimously concluding that Vance is the right leader for the company's growth period.
Vance brings 30 years of healthcare executive experience and has demonstrated decisive leadership in stabilizing the business, sharpening strategic focus, and rebuilding confidence among employees, customers, and shareholders.
AVITA Medical, a leading therapeutic acute wound care company, has appointed Cary Vance as President and Chief Executive Officer effective immediately, following his successful interim tenure since October 2025. The Board of Directors also appointed Jan Stern Reed as its Chair, marking a significant leadership transition for the company focused on innovative wound healing technologies.
Leadership Transition Reflects Strategic Confidence
The appointment follows a comprehensive search process conducted in coordination with a top-tier international executive search firm. "Following a thorough search process conducted in coordination with a top-tier, international executive search firm, the Board unanimously concluded that Cary is the right leader to serve as CEO on a permanent basis," said Jan Stern Reed, the newly appointed Chair of the AVITA Medical Board of Directors.
During his six-month interim period, Vance demonstrated decisive leadership at a critical time for the company, stabilizing the business, sharpening strategic focus, and rebuilding confidence and enthusiasm with employees, customers, and shareholders. His deep industry experience, operational discipline, and thorough understanding of the business position him well to lead the company into an exciting growth period.
Clinical Validation Drives Momentum
Vance emphasized the clinical impact of AVITA's products during his interim leadership. "Over the past several months, I've spent time with clinicians at meetings such as Boswick and the American Burn Association, as well as in leading burn and trauma centers. The feedback has been consistent: our products are driving clinically validated improvements in patient outcomes and meaningfully improving recovery," said Vance.
The company is building momentum with its focus on scaling adoption, supporting more clinicians in delivering better outcomes, and translating that momentum into consistent performance. Vance expressed his commitment to working closely with the team and Board to realize the full potential of AVITA's acute wound care platform.
Executive Leadership Experience
Vance has served on the AVITA Medical Board of Directors since 2023 and was previously appointed Chairman in 2025. He brings 30 years of experience driving value creation and commercializing innovative medical technologies. His executive background includes serving as President and Chief Executive Officer of several companies, including PhotoniCare (search), Inc., Titan Medical (search) Inc., OptiScan Biomedical (search), MyoScience (search), Hansen Medical (search), and XCath (search). Earlier in his career, he held senior leadership roles at Teleflex, Covidien, and GE HealthCare.
Board Leadership Strengthened
Jan Stern Reed, who has served on the AVITA Medical Board since 2021, brings over 35 years of legal and business management experience in the healthcare industry as both an executive leader and board member. She previously served as the Board's Lead Independent Director since October 2025, a role that was discontinued simultaneously with her appointment to the independent Chair position.
"Jan is a highly experienced independent director who has served on the Board since 2021, having most recently served as the Board's Lead Independent Director since October," added Dr. Michael Tarnoff, the Chair of the Board's Human Capital and Compensation Committee. "As Board Chair, she will continue to work closely with Cary and the rest of the Board to support AVITA Medical's strategic priorities and continued growth."
Company Platform and Products
AVITA Medical's technology platform is designed to optimize wound healing and accelerate patient recovery time. At the forefront of the platform is RECELL (search), which is FDA-approved for the treatment of thermal burn (search) and trauma wounds (search). RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin, offering an innovative solution for improved clinical outcomes at the point-of-care.
In the U.S., AVITA Medical holds exclusive rights to market, sell, and distribute Cohealyx (search), an AVITA Medical-branded collagen-based dermal matrix, and exclusive rights to manufacture, market, sell, and distribute PermeaDerm (search), a biosynthetic wound matrix. Internationally, RECELL (search) is approved to promote skin healing in thermal burn (search) and trauma wounds (search), with CE-marking in Europe, TGA certification in Australia, and PMDA approval in Japan.